ZFTA–RELA is the cancer-promoting protein product of a gene fusion. Analyses of accessible sites in the DNA–protein complex chromatin in developing mice show that ZFTA–RELA binds to chromatin modules ...

How do different cancer subtypes arise? Do they originate from distinct cells, or from a single multipotent cell capable of ...

Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, ...

The concept of permanent and irreversible cell cycle arrest (senescence) was initially regarded as a defence mechanism against tumour progression. However, ...

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to poor ...

Scientists at Pune's Agharkar Research Institute developed a nanomedicine targeting breast cancer cells by silencing key ...

Cancer cells can brainwash their neighbors. Like the CIA deploying secret agents to turn an enemy, tumors use a similar strategy to manipulate nearby cells. The tumors’ agents are mitochondria, the ...

Scientists have identified a 14-protein blood signature that may predict lung cancer risk more than five years before ...